Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Operating Expenses: 2010-2025

Historic Operating Expenses for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $82.1 million.

  • Catalyst Pharmaceuticals' Operating Expenses rose 5.58% to $82.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $319.4 million, marking a year-over-year increase of 11.49%. This contributed to the annual value of $296.6 million for FY2024, which is 4.75% down from last year.
  • Catalyst Pharmaceuticals' Operating Expenses amounted to $82.1 million in Q3 2025, which was up 2.32% from $80.3 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Operating Expenses registered a high of $139.9 million during Q3 2023, and its lowest value of $20.4 million during Q1 2021.
  • Its 3-year average for Operating Expenses is $77.1 million, with a median of $77.8 million in 2024.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Operating Expenses surged by 335.18% in 2023 and then tumbled by 44.39% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Operating Expenses (Quarterly) stood at $25.6 million in 2021, then rose by 17.17% to $30.0 million in 2022, then soared by 129.92% to $68.9 million in 2023, then grew by 14.67% to $79.0 million in 2024, then climbed by 5.58% to $82.1 million in 2025.
  • Its Operating Expenses was $82.1 million in Q3 2025, compared to $80.3 million in Q2 2025 and $78.1 million in Q1 2025.